Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct;37(5):578-583.
doi: 10.1097/JCP.0000000000000754.

An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women

Brent M Kious  1 , Hana Sabic, Young-Hoon Sung, Douglas G Kondo, Perry Renshaw
Affiliations
Clinical Trial

An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women

Brent M Kious et al. J Clin Psychopharmacol. 2017 Oct.

Abstract

Purpose: Many women with major depressive disorder (MDD) respond inadequately to standard treatments. Augmentation of conventional antidepressants with creatine monohydrate and 5-hydroxytryptophan (5-HTP) could correct deficits in serotonin production and brain bioenergetics associated with depression in women, yielding synergistic benefit. We describe an open-label study of 5-HTP and creatine augmentation in women with MDD who had failed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) monotherapy.

Methods: Fifteen women who were adequately adherent to an SSRI or SNRI and currently experiencing MDD, with a 17-item Hamilton Depression Rating Scale (HAM-D) score of 16 or higher, were treated with 5 g of creatine monohydrate daily and 100 mg of 5-HTP twice daily for 8 weeks, with 4 weeks of posttreatment follow-up. The primary outcome was change in mean HAM-D scores.

Results: Mean HAM-D scores declined from 18.9 (SD, 2.5) at pretreatment visits to 7.5 (SD, 4.4) (P < 0.00001), a decrease of 60%. Participants did not experience any serious treatment-related adverse events.

Conclusions: Combination treatment with creatine and 5-HTP may represent an effective augmentation strategy for women with SSRI- or SNRI-resistant depression. Given the limitations of this small, open-label trial, future study in randomized, placebo-controlled trials is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HAM-D scores over 8 weeks in women receiving SSRI/SNRI augmentation with 5-HTP and creatine. Active treatment provided through week 8; weeks 10 and 12 represent post-treatment follow-up. Error bars represent 95% confidence interval of the mean. Solid horizontal line indicates potential remission score (HAM-D=7). Asterisk (*) represents beginning of statistical significance compared to baseline (Sidak corrected p < 0.05). Dashed vertical line indicates the finish of 8 weeks of treatments.
Figure 2
Figure 2
MADRS scores over 8 weeks in women receiving SSRI/SNRI augmentation with 5-HTP and creatine. Active treatment provided through week 8; weeks 10 and 12 represent post-treatment follow-up. Error bars represent 95% confidence interval of the mean. Solid horizontal line indicates potential remission score (MADRS=10). Asterisk (*) represents beginning of statistical significance compared to baseline (Sidak corrected p < 0.05). Dashed vertical line indicates the finish of 8 weeks of treatments.
Figure 3
Figure 3
BAI scores over 8 weeks in women receiving SSRI/SNRI augmentation with 5-HTP and creatine. Active treatment provided through week 8; weeks 10 and 12 represent post-treatment follow-up. Error bars represent 95% confidence interval of the mean. Solid horizontal line indicates potential remission score (BAI=10). Asterisk (*) represents beginning of statistical significance compared to baseline (Sidak corrected p < 0.05). Dashed vertical line indicates the finish of 8 weeks of treatments.
See this image and copyright information in PMC

References

    1. Kessler RC, Berglund P, Demler OJ, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
    1. Birnbaum HG, Kessler RC, Kelley D, et al. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27:78–89. - PubMed
    1. van der Voort TY, Seldenrijk A, van Meijel B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015;76:809–814. - PubMed
    1. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999;18:163–171. - PubMed
    1. Bebbington PDG, Jenkins R, Lewis G, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Int Rev Psychiatry. 2003;15:74–83. - PubMed

Publication types